In case you have not noticed, this is traded OTC. Just read the science that you continue to ignore. Your diatribes are near term arguments, based on dilution threats, not fundamental value. I dare you to comment on the patent claims for this application.You know nothing about the implications because you have convinced yourself that basic accounting principles teaches you everything you need to know about a company. We aren't all that foolish.
Ocata will soon own the patent to hemangioblast-derived hESC MSCs to treat virtually all autoimmune disorders and immune reactions. What distinguishes them from all other MSC sources?
1) Earlier demonstration of cell markers
2) Doubling capability
3) Immune modulatory capability
They are an allogeneic source that can be produced at a much, much larger scale than any other source. The list of uses in claim 109 is astounding. Furthermore, just looking at the data tables and figures, hemangioblast-derived hESC MSCs do not clump like normal hESC; more easily disperse than normal hESC; replicate in much greater numbers than hESC; and acquire characteristic cell surface markers earlier than normal hESCs. Don't even mention bone marrow derived, adipose, or other MSC sources - these don't even come close.
You don't have to believe me, look at the application with the data that was just allowed for issuance as a patent. The winner (Ocata) will literally take all when it comes to autoimmune treatments using MSCs. This is cost cutting technology that will have far greater efficacy than any previously described MSC treatment.
Where does it mention pivotal? Seems like another fabrication. Must you always make these false claims - you are worse than the bashers.
You must be a fan of Asterias. I foresee ocata taking a similar collaborative approach as KRUK and Asterias, although it's unclear at this point whether a telomerase or antigen platform would be best. I assumed an antigen approach based on observed successes using autologous dc's. However, the verdict is still out on telomerase and you may be right. Nonetheless, Asterias and Ocata seem to both hold the scalability cards that no other companies can claim. If the survival rates are as good or better than the autologous approaches, then watch out for Asterias and Ocata.
You have your head in the clouds. Too many days flying jets or just narcissistic personality disorder? Research immune therapy for cancer treatments and then tell us nobody cares.
Antigen specific engineered dendritic cells. The dc's produced by ocata are the raw material for the likes of juno, kite, etc.
Has anyone seen Juno's IPO today? Immunotherapy is here to stay and Ocata's manufacturing methods for dendritic cells are unmatched in efficiency and potency. They have a patent on a gold standard cell source.
The prospectus was a red herring, i.e. preliminary, document. The company doesn't have to issue the shares to be listed on Nasdaq. No date was ever announced by the company. For all we know they could be waiting for January to uplist. They could then offer the shares on Nasdaq where there is far more liquidity. Alternatively they could announce a jv that would satisfy uplisting requirements. Don't allow shorts, pumpers, etc tell you otherwise. Just reread the language in the December 2 announcement. There are a lot of day traders here who want to time everything under the sun.
Bwaaaahaha... it's always burning AND freezing on the OTC smit - over 90% of investors can't buy this stock yet. And those short sales to drop the price are so tiny, it's almost hilarious. The selling does absolutely nothing to keep the price down. It comes swinging back up right away.
The large oscillations in share price are correlated with very small short sales. This has been going on all week. Folks are trying to drive the price down but it can't be sustained. They sell shares short only to dig themselves into a deeper hole. Is this desperation or simply an attempt to scare retails for the sake of acquiring more shares? It is a daytrader's dream right now. We are looking at +8% swings in short time spans.
A classic case of dilution. Just make sure you avoid all discussions about the science, market cap, trial results, market potential, pipeline, etc. People will start ignoring you if you did that. This kachina is gonna bring nothing but rain.
And yes I am still up, but let's play pretendsy and say I am down 99% to make it sound like the worst investment ever. That kachina doll experiment at ocata is something else. Do the Hopi know how ocrappa is ripping them off with the kachina sales? And 10 years sounds much worse than 3.5... good thinking. Thanks for looking out after all of us.
A big old lump of coal is right. They are just gonna dump those 10 million shares and do nothing with it, no value in the offering. I think it will be more like 10 days. Nasdaq is nothing new either, just another lump of anthracite.
Oh boy I should have sold last week. Thanks for looking after my well being. I will sell right now. So it was poor demand? And only $5 million in the coffers. So the offering will be priced at $0... I should have known, something seemed fishy. Thanks!
A partnership using Ocata's cells to treat various forms of cancer will take many by surprise. With anything that is commercialized, the ability to upscale is key. Ocata's scalability method using hemangioblast derived stem cells is now patent protected. Who is going to partner this one assuming they won't go it alone?
Ocata recently announced their patented scalability of hemangioblast derived dendritic cell production techniques. Why is this significant? Immunologic cancer therapies and vaccines are using dendritic cells in combination with t-cells to successfully target and destroy cancer cells. This approach is being used by the likes of Juno and Kite. Research their results and you will see why Ocata's patent is a huge development for the company and the cancer research community. Current treatments use autologous or bone marrow derived cells, not off the shelf dendritic cells. Mass production saves money and time. With all the commentary from cancer researchers expressing a need to upscale cell production, it makes me wonder who will take Ocata's technology and run with it. You mass produce dendritic cells- and eventually t-cells- and you have an off the shelf cancer therapy or vaccine that costs a fraction of the cost of autologous or bone marrow derived methods.